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Abstract 
This study attempts basically to measure the financial performance of the Pharmaceutical Industry taking top 
three companies like Cipla, Dr. Reddy’s Laboratories, Ranbaxy for the period 2003-2012. In order to achieve our 
goals in this paper we have  measured  the  ratios  of  ROE,  ROA  applying  the  DuPont  analyses, 
which have been demonstrated with the aim of tables to show the change periodically. DuPont analysis (ROI and 
ROE)) is an important tool for judging the operating financial performance. It is an indication of the earning 
power of the firm.  
DuPont Model which is based on analysis of Return on Equity (ROE) & Return on Investment (ROI). The return 
on equity disaggregates performance into three components: Net Profit Margin, Total Asset Turnover, and the 
Equity Multiplier. Return on Investment consists of Assets Turnover and Profit Margin. The return on investment 
consists of Assets Turnover (Operating Income X Total Assets) and Profit Margin (EBIT X Operating Income).  
From the study it if found that Cipla pharmaceutical Financial performance is high followed by Dr.Reddy’s La-
boratories and then Ranbaxy Pharmaceutical. The three companies are significant at their level. In conclusion, 
ROE & ROI is the most comprehensive measure of profitability of a firm. It considers the operating and invest-
ing decisions made as well as the financing and tax-related decisions 
Keywords: DuPont Analysis, Return on equity, Return on Investment, Financial Performance, Pharmaceutical 
Industry. 
 
1. Introduction 
For any business in the private sector there are numerous of models to describe how well the business is running. 
Among these the DuPont model was created in the early 1900s but is still a model valid to use for assessment of 
the profitability. Using the DuPont model for risk analysis is not very common but if you as a risk analysis spe-
cialist want to talk the language of the business, it can be valuable to you. 
The model was created by F. Donaldson Brown who came up with the model when he was assigned to 
clean up the finances in General Motors and has ever since been an important model for financial analysis. Re-
markably it has not been used in the security community for risk prioritization or impact analysis. The original 
DuPont method of financial ratio analysis was developed in 1918 by an engineer at DuPont who was charged 
with understanding the finances of a company that DuPont was acquiring. He noticed that the product of two 
often-computed ratios, net profit margin and total asset turnover, equals return on assets (ROA). The elegance of 
ROA being affected by a profitability measure and an efficiency measure led to the DuPont method becoming a 
widely-used tool of financial analysis Liesz, (2002). In the 1970’s, emphasis in financial analysis shifted from 
ROA to return on equity (ROE), and the DuPont model was modified to include the ratio of total assets to equity. 
Three distinct versions of Du Pont have been created and used to help unravel the underlying drivers of profita-
bility and return over time, beginning nearly 90 years ago. 
The DuPont Model is a useful tool in providing both an overview and a focus for such analysis. It can be 
used as a compass in the process by directing the analyst toward significant areas of strength and weakness evi-
dent in the financial statements. This study attempts basically to measure the financial performance of the Phar-
maceutical Industry in India. The main objective is to find out the ratios of ROE and ROI for top three pharma-
ceutical industries namely Cipla Pharmaceutical, Dr. Reddy’s Laboritories, Ranbaxy Pharmaceutical for a period 
10 years from 2003-2012. The aim of the study to rank the pharmaceutical industry and evaluate its financial 
performance based on DuPont analysis which includes ROE and ROI.  
Currently the Indian Pharmaceutical industry is valued at approximately 90,000 Crores or US $ 20 billion 
(1 US $ = 45), constituting 1.8% of the GDP and expected to grow more than 11% going forward. The country 
now ranks 3rd worldwide by volume of production and 14th by value thereby accounting for around 10% of 
world's production by volume and 1.5% by value. Globally, it ranks 4th in terms of generics production and 17th 
in terms of export value of bulk actives and dosage forms. Through to 2015 and 2020, India's pharmaceutical 
market will post local currency CAGRs of 14.6% and 13.5% respectively. It increases the value of shareholders 
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in the market and makes them to earn more. This is the reason the researcher attempts to evaluate the financial 
performance of pharmaceutical industry in India using DuPont Analysis. 
 
2.Concept of DuPont Model 
For any business in the private sector there are numerous of models to describe how well the business is running. 
Among these the DuPont model was created in the early 1900s but is still a model valid to use for assessment of 
the profitability. Using the DuPont model for risk analysis is not very common but if you as a risk analysis spe-
cialist want to talk the language of the business, it can be valuable to you. 
The model was created by F. Donaldson Brown who came up with the model when he was assigned to 
clean up the finances in General Motors and has ever since been an important model for financial analysis. Re-
markably it has not been used in the security community for risk prioritization or impact analysis. The original 
DuPont method of financial ratio analysis was developed in 1918 by an engineer at DuPont who was charged 
with understanding the finances of a company that DuPont was acquiring. He noticed that the product of two 
often-computed ratios, net profit margin and total asset turnover, equals return on assets (ROA). The elegance of 
ROA being affected by a profitability measure and an efficiency measure led to the DuPont method becoming a 
widely-used tool of financial analysis Liesz, (2002). In the 1970’s, emphasis in financial analysis shifted from 
ROA to return on equity (ROE), and the DuPont model was modified to include the ratio of total assets to equity. 
Before discussing the mechanics and usefulness of Du Pont, it may be of some interest to learn about its 
development. The maturation of the Du Pont model parallels the progress made in the field of financial analysis 
itself. Three distinct versions of Du Pont have been created and used to help unravel the underlying drivers of 
profitability and return over time, beginning nearly 90 years ago. 
In 1918, four years after he was hired by the E. I. du Pont Corporation of Wilmington, 
Delaware, to work in its treasury department, electrical engineer F. Donaldson Brown was given the task of 
untangling the finances of a company of which Du Pont had just purchased 23 percent of its stock. (This com-
pany was General Motors!) Brown recognized a mathematical relationship that existed between two commonly 
computed ratios, namely net profit margin (obviously a profitability measure) and total asset turnover (an effi-
ciency measure), and ROA. 
 
3. Review Literature 
For an investment to be acceptable to a firm’s financial management it must provide a positive answer to the 
question “Will the acquisition of this asset increase the value of the owner’s equity?” (F. Arditti, 1967) 
The financial objectives of a for-profit business primarily concern the needs of the external suppliers of debt and 
equity capital. The economic returns to shareholders comprise dividends and capital gains on the market value of 
their shares. As earning determine what can be paid out as dividend in the long run, shareholders are primarily 
concerned with financial measures like earnings, ROS, ROA, ROE, ROI. (R. Thorpe, J. Holloway, 2008) 
Du Pont analysis, a common form of financial statement analysis, decomposes return on net operating assets into 
two multiplicative components: profit margin and asset turnover (B. McClure). These two accounting ratios 
measure different constructs and, accordingly, have different properties. Prior research has found that a change in 
asset turnover is positively related to future changes in earnings (M. Soliman) 
Du Pont analysis takes into account three indicators to measure firm profitability: ROA, ROE and ROI. 
Return on assets – ROA offers a different take on management effectiveness and reveals how much profit a 
company earns for every dollar of its assets ([S. Ross, R. Westerfield, J. Jaffe, B. Jordan). Assets include 
things like cash in the bank, accounts receivable, property, equipment, inventory and furniture. Only a few pro-
fessional money managers will consider stocks with a ROA of less than 5%. 
ROA = Total Assets / Net income 
Return on equity – ROE It is a basic test of how effectively a company's management uses investors’ money – 
ROE shows whether management is growing the company's value at an acceptable rate. Also, it measures the 
rate of return that the firm earns on stockholder’s equity. Because only the stockholder’s equity appears in the 
denominator, the ratio is influenced directly by the amount of debt a firm is using to finance assets (B. 
McClure). Practically, ROE reflects the profitability of the firm by measuring the investors` return (J. J. Grif-
fin, J.F. Mahon).  
ROE = Stockholder’s equity/Total Assets X Total Assets/ Net income X Stockholder s equity / Total Assets 
ROE is calculated by taking the profit after tax and preference dividends of a given year and dividing it by the 
book value of equity (ordinary shares) at the beginning of the year. Average equity can also be used. Equity 
would consist of issued ordinary share capital plus the share premium and reserves [J.H.V.H. de Wet, E. du 
Toit].  
Return on Investment – ROI The return on investment is the return earned from the investment made by the 
firm. This gives the actual position of the firm. ROI shows whether the management is in profitable position or 
not. It measures the earnings of the firm. It multiplies profit margin and Asset Turnover. (B. McClure)  
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ROI = Assets Turnover (Operating Income X Total Assets) X Profit Margin (EBIT X Operating Income) 
Hawawini and Viallet (1999) offered yet another modification to the DuPont model. This modification resulted 
in five different ratios that combine to form ROE and ROI. In their modification they acknowledge that the fi-
nancial statements firms prepare for their annual reports (which are of most importance to creditors and tax col-
lectors) are not always useful to managers making operating and financial decisions. 
In order to more effectively evaluate operational managers, Nissim & Penman (2001) suggest using a modified 
version of the traditional DuPont model in order to eliminate the effects of financial leverage and other factors 
not under the control of those managers. Using operating income to sales and asset turnover based on operating 
assets limits the performance measure of management to those factors over which management has the most 
control. The modified DuPont model has become widely recognized in the financial analysis literature. See, for 
example, Pratt & Hirst (2008), Palepu & Healy (2008), and Soliman (2008). 
In addition, Soliman (2004) found that industry-specific DuPont multiplicative components provide more useful 
valuation than do economy-wide components, suggesting that industry-specific ratios have increased validity. 
Prendergast (2006) and Milbourn & Haight (2005) present examples of using DuPont analysis in both a busi-
ness and classroom setting. Prendergast illustrates how a “modified DuPont approach to ratio analysis can be 
used to drill down to the true cause of financial performance problems” in a small manufacturing business (p. 
48). Milbourn & Haight show the use of “Du Pont Analysis as a teaching aid to equip students with an under-
standing of how management decisions influence the bottom line” (p. 46). Unfortunately, the Milbourn & 
Haight paper is concerned exclusively with only the original Du Pont model, i.e. it shows the drivers of no more 
than Return on Assets. We will show the impact and value of the Du Pont model drivers on Return on Equity. 
Saunders (2000) provides a model of financial analysis for financial institutions based on the DuPont system of 
financial analysis return on equity model and return on investment model. The return on equity model disaggre-
gates performance into three components: net profit margin, total asset turnover, and the equity multiplier. The 
profit margin allows the financial analyst to evaluate the income statement and the components of the income 
statement. Total asset turnover allows the financial analyst to evaluate the left-hand side of the balance sheet: 
assets. The equity multiplier allows the financial analyst to evaluate the right-hand side of the balance sheet: lia-
bilities and owners equity 
Brigham and Houston, (2001) The modified model was a powerful tool to illustrate the interconnectedness of a 
firm’s income statement and its balance sheet, and to develop straight-forward strategies for improving the firm’s 
ROE. 
Sundararajan, et al (2002) Various measures of rates of return are used mainly for that purpose. We fully agree 
with the opinion that “Relaying too heavily on just a few indicators of bank profitability can be misleading. 
While ROI, ROE, and interest margin (and non interest expenses) to gross income remain the key measures, they 
should ideally be supplemented by the analysis of other operating ratios”  
Debasish Sur and kaushik Chakraborty (2006) in his study financial performance of Indian Pharmaceutical 
Industry: The Indian Pharmaceutical Industry has been playing a very significant role in increasing the life ex-
pectancy and in decreasing the mortality rate. It is the 5th largest in terms of volume and 14th largest in value 
terms I the world. The comparative analysis the financial performance of Indian pharmaceutical industry for the 
period 1993 to 2002 by selecting six notable companies of the industry. The comparison has been made from 
almost all points of view regarding financial performance using relevant statistical tools.  
T. Vanniarajan and C. Samuel Joseph (2007) in his study An Application of DuPont Control chart in Analyz-
ing the financial performance of Banks. The liberlization of the finance sector in India is exposing Indian banks 
to a new economic environment it is characterized by increased competition and new regulatory requirements. 
Indian and foreign banks are exploring growth opportunities in India by introducing new products for different 
customer segments, many of which were not conventionally viewed as customer for the Banks have, in the last 
ten years, witnessed new shareholders. All banks are in a position to evaluate its performance compared to oth-
ers. In general, the performance of the banks may be viewed on three dimensions namely structural, operational 
and efficiency factors are suggested by India Bank Association. 
Mihaela Herciu, Claudia Ogrean & Lucian Belascu(2011) The present paper aims to demonstrate that in most 
cases the most profitable companies are not the most attractive for investors – through Du Pont Analysis method. 
In order to do this, we take into account the top 20 most profitable companies in the world in 2009 (according to 
Fortune). By using Du Pont analysis we came to the results that the ranking is not preserved when indicators 
(ratios) such as ROA (return on assets) or ROI (return on Investment), ROE (return on equity) or ROS (return on 
sales) are taken into consideration. 
Dr Ahmed Arif Almazari (2012) This study attempts basically to measure the financial performance of the Jor-
danian Arab commercial bank for the period 2000-2009 by using the DuPont system of financial analysis which 
is based on analysis of return on equity model and return on investment model. The return on equity model dis-
aggregates performance into three components: net profit margin, total asset turnover, and the equity multiplier. 
It was found that the financial performance of Arab Bank is relatively steady and reflects minimal volatility in 
European Journal of Business and Management                                                    www.iiste.org 
ISSN 2222-1905 (Paper) ISSN 2222-2839 (Online) 
Vol 4, No.14, 2012 
 
87 
the return on equity. Net profit margin and total asset turnover exhibit relative stability for the period from 2001 
to 2009.The equity multiplier also show almost stable indicators for the period from2001-2005 and the ratios 
declined from 2006-2009 which indicates that the Arab bank had less financial leverage in the recent years, 
which means the bank is relying less on debt to finance its assets. 
 
4.  DuPont Analysis Computation 
The DuPont analysis computes variables from the income statement and balance sheet to determine a 
firm’s return on equity (ROE) & return on Investment (ROI). The formula is as follows: 
ROE = Profit Margin (Net Profit/Sales) X Asset Turnover (Sales/Total Assets) X Equity Mulitplier 
(Total Assets/Total Equity) 
Figure 1: Return On Equity 
ROI = Assets Turnover (Operating Income X Total Assets) X Profit Margin (EBIT X Operating Income) 
Figure 2: Return on Investment 
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Table 1: Showing ROE & ROI for Cipla Pharmaceutical 
1.A. Return on Equity 
Year 
Total Assets 
(a) 
Common 
stock Eq-
uity (b) 
Financial 
Leverage 
C=(a x b) 
NPM 
(d) 
TAT 
(e) 
ROA 
(d/e) 
ROE = 
FL*ROA 
2002-2003 1044.31 724.66 1.44 18.22 0.94 17.15 24.71 
2003-2004 1411.54 890.14 1.59 18.24 0.91 16.66 26.41 
2004-2005 1817.68 1070.08 1.70 16.97 0.80 13.63 23.15 
2005-2006 2220.08 1264.05 1.76 15.95 0.87 13.81 24.27 
2006-2007 2616.06 1553.63 1.68 18.17 0.86 15.66 26.36 
2007-2008 3458.33 1983.27 1.74 20.38 0.86 17.57 30.64 
2008-2009 4413.74 3236.27 1.36 18.75 0.82 15.14 20.64 
2009-2010 5733.21 3755.82 1.53 16.69 0.73 12.23 18.68 
2010-2011 6859.7 4350.75 1.58 14.84 0.76 11.32 17.85 
2011-2012 8443.93 5914.09 1.43 19.29 0.66 12.81 18.29 
MEAN 3801.86 2474.28 1.58 17.75 0.82 14.60 23.10 
STD.DEV 2500.77 1753.48 0.14 1.65 0.09 2.16 4.20 
t value 
Sig.  (2-tailed) 
4.808 
(0.001) 
4.462 
(0.001) 
35.804 
(0.000) 
34.114 
(0.000) 
30.343 
(0.000) 
21.337 
(0.000) 
17.397 
(0.000) 
 
1.B. Return on Investment 
Year 
Operating 
Income 
(a) 
Total as-
sets 
(b) 
Assets 
Turnover 
C=(a/b) 
EBIT 
(d) 
Operating 
Income 
(e) 
Profit 
Margin 
F=(d/e) 
ROI 
(C*F) 
2002-2003 233.45 1044.31 0.22 255.91 233.45 1.10 0.25 
2003-2004 306.48 1411.54 0.22 334.65 306.48 1.10 0.24 
2004-2005 319.42 1817.68 0.18 345.41 319.42 1.90 0.19 
2005-2006 422.38 2220.08 0.19 448.3 422.38 1.70 0.20 
2006-2007 505.29 2616.06 0.19 581.32 505.29 1.15 0.22 
2007-2008 693.89 3458.33 0.20 806.09 693.89 1.16 0.23 
2008-2009 821.83 4413.74 0.19 922.51 821.83 1.12 0.21 
2009-2010 852.17 5733.21 0.15 987.09 852.17 1.16 0.17 
2010-2011 1244.84 6859.70 0.18 1105.33 1244.84 0.89 0.16 
2011-2012 1380.93 8443.93 0.16 1506.64 1380.93 1.09 0.18 
MEAN 678.06 3801.86 0.19 729.33 678.07 1.24 0.21 
STD.DEV 398.06 2500.77 0.02 405.99 398.06 0.310 0.03 
t value 
Sig. (2-tailed) 
5.39 
(0.000) 
4.81 
(0.001) 
26.41 
(0.000) 
5.68 
(0.000) 
5.39 
(0.000) 
12.61 
(0.000) 
21.41 
(0.000) 
 
Inference:  
From the above table 1.A. ROE it is clear that mean value is 23.10, Std.dev is 4.20, the t-value is 17.397 and it is 
significant at 1% level of significance (.000).  In table 1.B. ROI it shows that the mean value is 0.21, std.dev is 
0.03, the t-value is 21.41 and it is significant at 1% level of significance (0.000) 
 
European Journal of Business and Management                                                    www.iiste.org 
ISSN 2222-1905 (Paper) ISSN 2222-2839 (Online) 
Vol 4, No.14, 2012 
 
89 
Table 2: Showing ROE & ROI for Dr. Reddy’s Laboratories  
2.A.  Return on Equity 
Year 
Total 
Assets 
(a) 
Common 
stock Eq-
uity (b) 
Financial 
Leverage 
C=(axb) 
NPM 
(d) 
TAT 
(e) 
ROA 
(d/e) 
ROE = 
FL*ROA 
2002-2003 1063.06 553.26 1.92 15.71 0.87 13.59 26.11 
2003-2004 1719.09 1457.99 1.18 30.77 0.87 26.74 31.53 
2004-2005 2166.06 1806.92 1.20 25.56 0.71 18.10 21.70 
2005-2006 2519.09 2047.02 1.23 17.05 0.66 11.24 13.83 
2006-2007 2982.01 2074.08 1.44 4.23 0.51 2.20 3.16 
2007-2008 3984.97 2262.14 1.76 10.54 0.50 5.30 9.33 
2008-2009 5958.19 4373.36 1.36 31.11 0.63 19.75 26.91 
2009-2010 6661.83 4811.81 1.39 14.21 0.50 7.13 9.88 
2010-2011 7357.50 5259.10 1.40 14.02 0.54 7.62 10.67 
2011-2012 8361.00 5914.60 1.41 19.25 0.53 10.12 14.31 
MEAN 4277.28 3056.03 1.43 18.24 0.63 12.18 17.00 
STD.DEV 2600.50 1850.93 0.24 8.66 0.14 7.49 9.26 
t value 
Sig. (2-tailed) 
5.201 
(0.001) 
5.221 
(0.001) 
18.878 
(0.000) 
6.664 
(0.000) 
14.053 
(0.000) 
5.143 
(0.001) 
5.715 
(0.000) 
 
2.B. Return on Investment 
Year 
Operating 
Income 
(a) 
Total 
assets 
(b) 
Assets 
Turnover 
C=(a/b) 
EBIT 
(d) 
Operating 
Income 
(e) 
Profit 
Margin 
F=(d/e) 
ROI 
(C/F) 
2002-2003 261.28 1063.06 0.25 257.80 261.28 0.99 0.24 
2003-2004 572.49 1719.09 0.33 626.64 572.49 1.09 0.36 
2004-2005 460.65 2166.06 0.21 498.04 460.65 1.08 0.23 
2005-2006 346.79 2519.09 0.14 379.31 346.79 1.09 0.15 
2006-2007 163.21 2982.01 0.05 154.8 163.21 0.95 0.05 
2007-2008 317.07 3984.97 0.08 413.05 317.07 1.30 0.10 
2008-2009 1327.35 5958.19 0.22 1561.3 1327.35 1.18 0.26 
2009-2010 582.70 6661.83 0.09 779.99 582.70 1.34 0.13 
2010-2011 758.00 7357.5 0.10 970.20 758.00 1.28 0.13 
2011-2012 1088.5 8361 0.13 1342.5 1088.50 1.23 0.16 
MEAN 587.80 4277.28 0.16 698.36 587.80 1.15 0.18 
STD.DEV 374.36 2600.50 0.09 466.45 374.36 0.13 0.09 
t value 
Sig. (2-tailed) 
4.965 
(0.001) 
5.201 
(0.001) 
5.681 
(0.000) 
4.735 
(0.001) 
4.965 
(0.001) 
27.311 
(0.000) 
6.291 
(0.000) 
 
Inference: 
From the above table 2.A. ROE it is clear that mean value is 17.00, Std.dev is 9.26, the t-value is 5.715 and it is 
significant at 1% level of significance (0.000).  In table 2.B. ROI it shows that the mean value is 0.18, std.dev is 
0.09, the t-value is 6.291 and it is significant at 1% level of significance (0.000) 
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Table 3: Showing ROE & ROI for Ranbaxy Pharmaceutical 
3. A. Return on Equity  
Year 
Total Assets 
(a) 
Common 
stock Eq-
uity (b) 
Financial 
Leverage 
C=(axb) 
NPM 
(d) 
TAT 
(e) 
ROA 
(d/e) 
ROE = 
FL*ROA 
2002-2003 2452.86 1606.98 1.53 12.14 0.85 10.27 15.68 
2003-2004 2823.13 1882.81 1.50 20.49 1.08 22.09 33.12 
2004-2005 3599.72 2321.77 1.55 20.83 1.06 22.08 34.23 
2005-2006 4187.72 2509.51 1.67 13.91 0.91 12.60 21.02 
2006-2007 4804.67 2377.3 2.02 5.83 0.76 4.41 8.92 
2007-2008 7036.85 2350.01 2.99 9.12 0.59 5.41 16.19 
2008-2009 7956.91 2538.4 3.13 14.38 0.54 7.76 24.34 
2009-2010 12013.46 3716.77 3.23 -22.46 0.39 -8.70 -28.11 
2010-2011 11328.91 4134.60 2.74 11.96 0.42 5.05 13.83 
2011-2012 12782.01 5132.40 2.49 20.35 0.44 8.99 22.38 
MEAN 6898.62 2857.06 2.29 10.66 0.70 9.00 16.16 
STD.DEV 3951.56 1108.37 0.71 12.67 0.26 8.95 17.52 
t value 
Sig. (2-tailed) 
5.52 
(.000) 
8.15 
(.000) 
10.19 
(.000) 
2.66 
(.026) 
8.46 
(.000) 
3.18 
(.011) 
2.91 
(.017) 
3. B. Return on Investment 
Year 
Operating 
Income 
(a) 
Total assets 
(b) 
Assets 
Turnover 
C=(a/b) 
EBIT 
(d) 
Operating 
Income 
(e) 
Profit 
Margin 
F=(d/e) 
ROI 
(C/F) 
2002-2003 297.95 2452.86 0.12 393.36 297.95 1.32 0.16 
2003-2004 723.96 2823.13 0.26 801.62 723.96 1.11 0.28 
2004-2005 915.65 3599.72 0.25 1031.94 915.65 1.13 0.29 
2005-2006 632.65 4187.72 0.15 697.43 632.65 1.10 0.17 
2006-2007 185.44 4804.67 0.04 307.69 185.44 1.66 0.06 
2007-2008 632.27 7036.85 0.09 603.62 632.27 0.96 0.09 
2008-2009 414.59 7956.91 0.05 965.72 414.59 2.33 0.12 
2009-2010 256.17 12013.46 0.02 -1331.47 256.17 -5.20 -0.11 
2010-2011 652.64 11328.91 0.06 1138.3 652.64 1.74 0.10 
2011-2012 1271.03 12782.01 0.10 1833.48 1271.03 1.44 0.14 
MEAN 598.24 6898.62 0.11 644.17 598.24 0.76 0.13 
STD.DEV 330.96 3951.56 0.08 817.92 330.96 2.13 0.11 
t value 
Sig. (2-tailed) 
5.716 
(0.000) 
5.521 
(0.000) 
4.301 
(0.002) 
2.491 
(0.034) 
5.716 
(0.000) 
1.125 
(0.290) 
3.624 
(0.006) 
 
Inference: 
From the above table 3.A. ROE it is clear that mean value is 16.16, Std.dev is 17.52, the t-value is 2.91 and it is 
significant at 5% level of significance (0.017).  In table 3.B. ROI it shows that the mean value is 0.13, std.dev is 
0.11, the t-value is 3.624 and it is significant at 5% level of significance (0.006). 
 
5. Conclusion 
The company profitability for most investors is a landmark in terms of earnings they could obtain by placing 
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capital. Profits earned by a company, taken the absolute amount, provides an overview of a company’s activity 
without giving details about the extent to which the company manages dividends, debts, liabilities or other indi-
cators. 
In this paper it is tried to demonstrate with the help of profitability ratios like ROI and ROE that the com-
parison of performance and condition of a company against its competitors, analyzing trends in the returns of a 
company in the context of trends of the components and forecasting the returns of a company based on forecasts 
of the components. 
From the above analysis it is found that Cipla pharmaceutical ROE and ROI has highest returns on equity 
and Investment by 23.10 and 0.21 followed by Dr. Reddy’s Laboratories ROE is 17.00 and ROI is 0.18. The 
third position secured by Ranbaxy Laboratories ROE is 16.16 and ROI by 0.13. This shows Cipla is concentrat-
ing on its financial performance by reducing its expenses and cost.     
As a conclusion, the Du Pont analysis that we made (by calculating ROI and ROE) for the top 3 most prof-
itable pharmaceutical companies in India emphasize that absolute measurements are not relevant every time. 
Therefore to have a common basis of comparison between several companies and to compose ranks the relative 
sizes for measuring efficiency are necessary when calculating the ratio. 
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